9

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE work Reduction of information unless it contains a valid OMB control number.

Substitute for form RAPTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

Complete if Known			
Application Number	10/349,431		
Filing Date	January 22, 2003		
First Named Inventor	Karen Gibson		
Art Unit	1614		
Examiner Name	James H. Reamer		
Attorney Docket Number	330499-00007		

			U. S. PATEN	T DOCUMENTS		
Examiner Cite No.1		Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
X		^{US-} 5,760,032	06-02-1998	Kitajima et al.	1	
(3)		^{US-} 2003/0139396 A1	07-24-2003	Gibson	1	
7	. 6	^{US-} 5,153,191	10-06-1992	Woodruff		
		US-			1	
		US-				
		US-				
		US-				
		US-				····
		US-				
		US-				
		US-				+
		US-				
		US-			+	
		US-			- 	
•		US-			+	
		US-				
-		US-				-
		US-		-		+
		US-			-	'

	FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials Cite Foreign Patent Document No.1 Country Code ³ Number ⁴ Kind Code ⁴ (# known)	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
	MM-DD-YYYY	, prison of once obtained	Or Relevant Figures Appear		
	EP 0 434 364	06-26-1991	Merk & Co Inc.	(厂
	WO 03/061632	07-31-2003	Karen Jackson		
					L
				 	L
					<u> </u>
	No.¹	Country Code ³ "Number ⁴ "Kind Code ³ (if known)	Cite No.¹ Foreign Patent Document Publication Date MM-DD-YYYY Country Code³ Number ⁴ Kind Code⁵ (if known) 06-26-1991	No.1 Date MM-DD-YYYY Country Code3 Number 1 Kind Code3 (# known) EP 0 434 364 Date MM-DD-YYYY Applicant of Cited Document MM-DD-YYYY Applicant of Cited Document MM-DD-YYYY	Cite No.1 Foreign Patent Document Country Code3 Number 4 Kind Code5 (if known) EP 0 434 364 Publication Date MM-DD-YYYY Publication Date MM-DD-YYYY Publication Date MM-DD-YYYY Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear O6-26-1991 Merk & Co Inc.

Examiner Signature Date Considered 9-20-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/349,431 INFORMATION DISCLOSURE **Filing Date** January 22, 2003 STATEMENT BY APPLICANT **First Named Inventor** Karen Gibson **Art Unit** 1614 (Use as many sheets as necessary) **Examiner Name** James H. Reamer Attorney Docket Number Sheet 330499-00007

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Y		L. BUENO, Involvement of brain CCK in the adaptation of gut motility to digestive status and stress: A review, J Physiology (1993) vol. 87, pp. 301-306	
(6)		J. FIORAMONTI, et al., Involvement of a CCK-dependent capsaicin-sensitive afferent pathway in the inhibitory effect of pinaverium bromide on the colonic motor response to eating in rats, Fundam Clin Pharmacol 1997:11:231-236	
3		C. BEGLINGER, Effect of Cholecystokinin on Gastric Motility in Humans, Annals New York Acadamy of Sciences, Vol 713, Issue 1, pp. 219-225	
G		M. D'AMATO, et al., Cholecystokinin-A receptor antagonists: therepies for gastrointestinal disorders, Exp. Opin. Invest. Drugs (1997) 6(7) pp. 819-836	
(6)		J.G. WETTSTEIN, et al., CCK Antagonists: Pharmacology And Thereputic Interest, Pharmac. Ther., (1994), vol 62, pp. 267-282	
3		WILLIAMS, CYNTHIA et al., Cholecystokinin-induced antinociception is not blocked by CCCK-A or CCCK-B receptor antagonists, Peptides(Terrytown), 18(3) 1997 pp.409-414	
		SINGH, L. et al., Modulation of the in vivo actions of morphine by the mixed CCKA/B receptor antagonist PD 142898, European Journal of Pharmacology, Amsterdam, NL, 307(3) 1996, pp. 283-289	
2		C.T. DOURISH et al., The Cholecystokinin Receptor Antagonist Devazepide Enhances Morphine-Induced Respiratory Depression in the Squirrel Monkey, The Journal of Pharmacology and Experimental Theraputics, vol. 255, No. 3, 1990, pp. 1158-1164	
(3)		JOEL HARDMAN et al., Goodman & Gilman's The Pharmacological basis of Therapeutics, 9th Edition, 1996, pp. 526-529 and 540-545	

Evaminor	. 04		Date	
Examiner			Date	0 2
Signature	1 /3 /		Considered	7-30-04
*EYAMINED: Initial if manifestation of substitution or not citation is in conformance with MOCO 600. Draw line through citation if not in conformance and not				

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.